Biopharmaceutical company specializing in advancing psychedelic therapeutic Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) announced having completed its 51st pre-clinical psychedelic molecule study.
The company now continues to progress its psychedelic molecules into Investigational New Drug (IND) enabling studies. The company’s continued development thesis is based on the need to create commercially viable psychedelics drugs.
These research programs support the company’s clinical goals including decreasing the initial time for therapeutic window which would include maximum convenience for people the treating therapist and the patient.
“These experiments greatly expand our understanding of the potential therapeutic value of the studied compounds and further demonstrate Cybin’s strong research and development capabilities,” said the company’s chief executive, Doug Drysdale.